We are happy to announce that on July 30, 2019, the Food and Drug Administration (FDA) approved a new drug, darolutamide (NUBEQA®, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of men with non-metastatic castration-resistant prostate cancer.
ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
At the recent ASCO GU conference, we learned the results from the ARAMUS phase III trial which evaluated Darolutamide, an androgen receptor (AR) antagonist (a drug that prevents androgens from affecting prostate and prostate cancer cells). The trial studied the efficacy and safety of darolutamide in men with nmCRPC men.
ARAMIS Trial Finds That the Investigational Treatment Darolutamide Extends Metastasis-free Survival of Men with M0 Castrate Resistant Prostate Cancer
It has been announced that the Phase III ARAMIS Trial (Androgen Receptor inhibiting Agent for Metastatic-free Survival) evaluating an investigational treatment known as darolutamide in men with Non-metastatic Castration-resistant Prostate Cancer (nM0) has successfully met its primary endpoint of extending the metastasis-free survival (MFS) of men compared to placebo.